日报更新时间：07-02 06:53
周报更新时间：01-23 11:54
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
中文名称：CASI制药
英文名称：CASI Pharmaceuticals
简介：CASI制药公司是一家临床阶段的制药公司，主要开发用于治疗癌症和炎症疾病的新一代多机制药物
电话：1-240-8642600
CASI是一家生物制药公司，专注于优质药品的收购，开发和商业化以及针对全球市场解决癌症和其他未满足医疗需求的创新疗法，重点关注大中华地区和美国。公司是纳斯达克上市公司，总部位于马里兰州罗克维尔，在中国北京设有全资子公司和研发中心。CASI制药的使命是成为一家在中国拥有巨大市场份额的综合性生物制药公司，同时建立全球发展和商业化的合作伙伴关系。公司的战略的一部分是利用其在中国和美国的专业知识和资源，为患者提供高质量的药品和创新的抗肿瘤产品，并利用其中国 - 美国双重身份，更具成本效益地开发药物。CASI的产品组合包括：1）Spectrum Pharmaceuticals, Inc.旗下经FDA批准上市的药物，由公司授权许可在中国地区销售的：注射用EVOMELA®（美法仑）、MARQIBO®，（vinCRIStine硫酸盐LIPOSOME注射液）、ZEVALIN®（ibritumomab tiuxetan）2）ENMD-2076（ II 期临床阶段）3）用于治疗乙型肝的炎恩替卡韦（entecavir）和其他美国ANDA产品4）CASI-001和CASI-002，专有的免疫肿瘤学临床前候选药物。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2016-10-27 | Spectrum Pharmaceuticals Inc | Beneficial Owner of More than 10% Class | Buy | 773790 | 0.01 |
| 2016-10-27 | Spectrum Pharmaceuticals Inc | Beneficial Owner of More than 10% Class | Buy | 521692 | 0.01 |
| 2016-10-27 | Spectrum Pharmaceuticals Inc | Beneficial Owner of More than 10% Class | Buy | 294815 | 0.01 |
| 2016-10-27 | Spectrum Pharmaceuticals Inc | Beneficial Owner of More than 10% Class | Buy | 198765 | 0.01 |
| 2016-10-02 | He (Wei-Wu) | Director | Buy | 1871605 | 1.19 |
| 2016-07-19 | Spectrum Pharmaceuticals Inc | Beneficial Owner of More than 10% Class | Buy | 98271 | -- |
| 2016-07-19 | Spectrum Pharmaceuticals Inc | Beneficial Owner of More than 10% Class | Buy | 66255 | -- |
| 2016-07-13 | Spectrum Pharmaceuticals Inc | Beneficial Owner of More than 10% Class | Buy | 585790 | -- |
| 2016-07-13 | Spectrum Pharmaceuticals Inc | Beneficial Owner of More than 10% Class | Buy | 394942 | -- |
| 2016-06-23 | Sparkle Byte Ltd | Beneficial Owner of More than 10% Class | Buy | 3753855 | 1.19 |
| 2016-02-21 | Spectrum Pharmaceuticals Inc | Beneficial Owner of More than 10% Class | Buy | 680113 | 0.01 |
| 2016-02-21 | Spectrum Pharmaceuticals Inc | Beneficial Owner of More than 10% Class | Buy | 1008764 | 0.01 |
| 2016-01-18 | Ren (Ken K) | Chief Executive Officer | Buy | 300 | 0.71 |
| 2016-01-18 | Hu (Cynthia Wong) | Chief Operating Officer | Buy | 11837 | 0.72 |
| 2016-01-18 | Hu (Cynthia Wong) | Chief Operating Officer | Buy | 400 | 0.75 |
| 2016-01-18 | Hu (Cynthia Wong) | Chief Operating Officer | Buy | 400 | 0.75 |
| 2016-01-18 | Hu (Cynthia Wong) | Chief Operating Officer | Buy | 4163 | 0.72 |
| 2016-01-18 | Ren (Ken K) | Chief Executive Officer | Buy | 1100 | 0.74 |
| 2016-01-18 | Ren (Ken K) | Chief Executive Officer | Buy | 7537 | 0.73 |
| 2016-01-18 | Ren (Ken K) | Chief Executive Officer | Buy | 1100 | 0.74 |
| 2016-01-18 | Ren (Ken K) | Chief Executive Officer | Buy | 6063 | 0.72 |
| 2016-01-18 | Ren (Ken K) | Chief Executive Officer | Buy | 7537 | 0.73 |
| 2016-01-18 | Ren (Ken K) | Chief Executive Officer | Buy | 300 | 0.71 |
| 2016-01-18 | Ren (Ken K) | Chief Executive Officer | Buy | 6063 | 0.72 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Teachers Advisors LLC | 107422 | 0.11% | -- | -- | 2019-03-31 |
| State Street Corporation | 795175 | 0.83% | 28868 | 3.77% | 2019-03-31 |
| Northern Trust Investments Inc | 973110 | 1.02% | 28269 | 2.99% | 2019-07-31 |
| Wellington Shields & Co., LLC | 1126650 | 1.18% | 46000 | 4.26% | 2019-03-31 |
| Wellington Shields Capital Mgmt LLC | 1145949 | 1.20% | -31182 | -2.65% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 1285278 | 1.34% | -- | -- | 2019-07-31 |
| BlackRock Fund Advisors | 1675884 | 1.75% | 2155 | 0.13% | 2019-07-31 |
| Vanguard Group Inc | 2331167 | 2.44% | 116638 | 5.27% | 2019-03-31 |
| BlackRock Inc | 2738109 | 2.86% | -98823 | -3.48% | 2019-03-31 |
| Geode Capital Management, LLC | 622336 | 0.65% | -547604 | -46.81% | 2019-03-31 |
| Northern Trust Corp | 600509 | 0.63% | 458 | 0.08% | 2019-03-31 |
| Northern Trust Investments N A | 600509 | 0.63% | 458 | 0.08% | 2019-03-31 |
| California Public Employees Retrmnt Sys | 139600 | 0.15% | -- | -- | 2019-03-31 |
| AXA Equitable Funds Management Group, LLC | 141827 | 0.15% | -- | -- | 2019-07-31 |
| BlackRock Institutional Trust Company NA | 178940 | 0.19% | -13118 | -6.83% | 2019-07-31 |
| ALPS Advisors Inc | 230154 | 0.24% | 9939 | 4.51% | 2019-03-31 |
| Charles Schwab Investment Management Inc | 253751 | 0.27% | -19645 | -7.19% | 2019-03-31 |
| BlackRock | 307971 | 0.32% | -16322 | -5.03% | 2019-07-31 |
| State Street Global Advisors | 429247 | 0.45% | -- | -- | 2019-07-31 |
| Fidelity Management & Research Company | 581643 | 0.61% | 20623 | 3.68% | 2019-07-31 |
| BlackRock Asset Management Canada Ltd | 1070775 | 1.12% | -882 | -0.08% | 2019-05-31 |
| Bank of New York Mellon Corp | 172947 | 0.18% | 19781 | 12.91% | 2018-12-31 |
| BNY Mellon Investment Management | 139354 | 0.15% | 19596 | 16.36% | 2018-12-31 |
| Deutsche Bank AG | 99968 | 0.11% | 18156 | 22.19% | 2018-09-30 |
| TIAA-CREF Investment Management LLC | 199536 | 0.21% | 88664 | 79.97% | 2018-09-30 |
| Morgan Stanley & Co Inc | 145388 | 0.16% | 51634 | 55.07% | 2018-06-30 |
| Morgan Stanley - Brokerage Accounts | 147257 | 0.16% | 51745 | 54.18% | 2018-06-30 |
| Goldman Sachs Group Inc | 178063 | 0.19% | 159202 | 844.08% | 2018-03-31 |
| Goldman, Sachs & Co. | 178063 | 0.19% | 159202 | 844.08% | 2018-03-31 |
| Royce & Associates, LP | 120000 | 0.13% | 120000 | -- | 2018-06-30 |
| California State Teachers Retirement Sys | 76371 | 0.09% | 76371 | -- | 2018-06-30 |
| Teachers Advisors Inc | 95606 | 0.11% | 95606 | -- | 2018-06-30 |
| Northern Trust Asset Management | 121020 | 0.14% | 76 | 0.06% | 2018-07-31 |
| Royce & Associates, LLC | 120000 | 0.14% | 120000 | -- | 2018-06-30 |
| State Street Corp | 593163 | 0.69% | 569534 | 2410.32% | 2018-06-30 |
| WEALTH STRATEGY HOLDING Ltd. | 6296292 | 9.24% | 6296292 | -- | 2017-10-23 |
| Spectrum Pharmaceuticals Inc | 11547675 | 13.42% | 6142293 | 113.63% | 2018-04-17 |
| T. Rowe Price Associates, Inc. | 49733 | 0.06% | 333 | 0.67% | 2018-06-30 |
| AQR Capital Management LLC | 76350 | 0.09% | 76350 | -- | 2018-06-30 |
| Susquehanna Financial Group, LLLP | 140680 | 0.18% | 116139 | 473.24% | 2018-03-31 |
| Millennium Management LLC | 430297 | 0.54% | 388083 | 919.32% | 2018-03-31 |
| LAURION CAPITAL MANAGEMENT LP | 55729 | 0.07% | 55729 | -- | 2018-03-31 |
| Raymond James Finl Svs Advisors, Inc. | 52090 | 0.07% | 32000 | 159.28% | 2018-03-31 |
| BlackRock Advisors (UK) Ltd | 46200 | 0.06% | -17679 | -27.68% | 2018-03-31 |
| Renaissance Technologies Corp | 41800 | 0.05% | -108800 | -72.24% | 2018-03-31 |
| Perceptive Advisors LLC | 43682 | 0.05% | -40000 | -47.80% | 2018-03-31 |
| Susquehanna International Group, LLP | 140680 | 0.18% | 116139 | 473.24% | 2018-03-31 |
| Moors & Cabot Inc | 24663 | 0.04% | -1390 | -5.34% | 2017-12-31 |
| ALPINE SECURITIES USVI LLC | 27729 | 0.04% | 27729 | -- | 2017-12-31 |
| Mellon Capital Management Corporation | 33402 | 0.04% | 28331 | 558.69% | 2018-03-31 |
| Citadel Advisors Llc | 18398 | 0.03% | 18398 | -- | 2017-12-31 |
| Virtu Financial LLC | 40790 | 0.07% | 40790 | -- | 2017-09-30 |
| ZHEJIANG KANGLAITE GROUP CO Ltd | 4938269 | 8.20% | 2880656 | 140.00% | 2016-12-31 |
| Royal Bank Of Canada | 17649 | 0.03% | 77 | 0.44% | 2017-12-31 |
| Guggenheim Capital LLC | 12242 | 0.02% | 12242 | -- | 2017-09-30 |
| FMG LLC | 5972 | 0.01% | -- | -- | 2018-01-31 |
| BlackRock Advisors LLC | 7740 | 0.01% | -- | -- | 2018-01-31 |
| Everett Harris & Co | 10002 | 0.02% | -- | -- | 2017-12-31 |
| Manatuck Hill Partners LLC | 15090 | 0.03% | -- | -- | 2017-09-30 |
| Howland Capital Management Inc | 24139 | 0.04% | 24139 | -- | 2017-09-30 |
| USAA Asset Management Company | 7740 | 0.01% | -- | -- | 2017-09-30 |
| Guggenheim Funds Investment Advisors LLC | 10883 | 0.02% | -- | -- | 2017-12-20 |
| Williams Jones & Associates Inc | 17812 | 0.04% | -- | -- | 2016-09-30 |
| He Xie Ai Qi Investment Management (Beijing) Co Ltd | 8498765 | 17.90% | -- | -- | 2016-07-27 |
| Celgene Corporation | 2464987 | 4.00% | 3664203 | 0.10% | 1999-11-30 |
| Spectrum Pharmaceuticals, Inc. and affiliated entities | 5405382 | 4.00% | 8035100 | 0.20% | 1999-11-30 |
| IDG-Accel China and affiliated entities | 6842783 | 4.00% | 10171797 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| NT R2000 Growth Index Fund - Non-Lending | 191434 | 0.20% | -- | -- | 2019-06-30 |
| EQ/2000 Managed Volatility Portfolio | 75132 | 0.08% | -- | -- | 2019-05-31 |
| Vanguard Total Stock Market Index Fund | 1285278 | 1.34% | -- | -- | 2019-06-30 |
| iShares Russell 2000 ETF | 1044775 | 1.09% | 2046 | 0.20% | 2019-07-30 |
| Vanguard Extended Market Index Fund | 736255 | 0.77% | -- | -- | 2019-06-30 |
| iShares Russell 2000 Growth ETF | 413202 | 0.43% | -- | -- | 2019-07-30 |
| State Street Russell Small Cap | 203924 | 0.21% | -- | -- | 2019-06-30 |
| State Street Russell Small/Mid Cap | 196821 | 0.21% | -- | -- | 2019-06-30 |
| NT R2000 Index Fund - NL | 192597 | 0.20% | 7631 | 4.13% | 2019-06-30 |
| Schwab US Small-Cap ETF | 152690 | 0.16% | 130 | 0.09% | 2019-07-31 |
| BlackRock Extended Equity Market | 94103 | 0.10% | -129 | -0.14% | 2019-06-30 |
| Northern Trust Russell 2000 Index DC NL | 146213 | 0.15% | 5176 | 3.67% | 2019-06-30 |
| NT R2000 Growth Index Fund - Lending | 135492 | 0.14% | 2172 | 1.63% | 2019-06-30 |
| iShares Micro-Cap ETF | 128847 | 0.13% | -- | -- | 2019-07-30 |
| Schwab Small Cap Index Fund | 105221 | 0.11% | -- | -- | 2019-06-30 |
| Russell 2000 Index Non-Lendable Fund E | 97484 | 0.10% | -13117 | -11.86% | 2019-06-30 |
| Fidelity | 79991 | 0.08% | -- | -- | 2019-06-30 |
| The Vanguard - Russell 2000 Grwth Idx CF | 88275 | 0.09% | 14088 | 18.99% | 2019-06-30 |
| BlackRock Russell 2000 | 81070 | 0.08% | 1333 | 1.67% | 2019-03-31 |
| ALPS Medical Breakthroughs ETF | 228062 | 0.24% | -- | -- | 2019-05-31 |
| iShares US Small Cap ETF (CAD-Hedged) | 996973 | 1.04% | -1674 | -0.17% | 2019-05-30 |
| AXA 2000 Managed Volatility Portfolio | 75132 | 0.08% | -- | -- | 2019-01-31 |
| TIAA-CREF Small-Cap Blend | 73710 | 0.08% | -- | -- | 2019-01-31 |
| iShares Russell 2000 Small-Cap Index Fd | 60139 | 0.06% | -- | -- | 2019-02-28 |
| CREF Stock Account | 65481 | 0.07% | 1275 | 1.99% | 2019-01-31 |
| AQR Small Cap Momentum Style Fund | 65581 | 0.07% | -10573 | -13.88% | 2018-12-31 |
| Vanguard Russell 2000 Index Fund | 58961 | 0.06% | -900 | -1.50% | 2019-01-31 |
| LVIP SSgA Small Cap Index Fund | 50700 | 0.05% | -- | -- | 2018-12-31 |
| iShares Russell 2000 Value ETF | 49946 | 0.05% | -- | -- | 2019-01-31 |
| Vanguard Balanced Index Fund | 49361 | 0.05% | -- | -- | 2019-01-31 |
| Vanguard Instl Total Stock Market Idx Fd | 47384 | 0.05% | -- | -- | 2019-01-31 |
| Master Small Cap Index Series | 60139 | 0.06% | -- | -- | 2018-12-31 |
| Royce Smaller-Companies Growth Fund | 78742 | 0.08% | -41258 | -34.38% | 2018-09-30 |
| Fidelity Spartan | 84183 | 0.10% | -- | -- | 2018-07-31 |
| The Vanguard Russell 2000 Growth Index | 82729 | 0.10% | 2810 | 3.52% | 2018-07-31 |
| BlackRock Russell 2500 | 67563 | 0.08% | 67563 | -- | 2018-06-30 |
| AXA 2000 Managed Volatility K | 75132 | 0.09% | 2984 | 4.14% | 2018-07-31 |
| AQR Small Cap Momentum Style I | 65365 | 0.08% | 65365 | -- | 2018-06-30 |
| CREF Stock R1 | 73173 | 0.08% | -3862 | -5.01% | 2018-07-31 |
| TIAA-CREF Small-Cap Blend Idx Inst | 60885 | 0.07% | -- | -- | 2018-07-31 |
| Vanguard Russell 2000 ETF | 56508 | 0.07% | 1050 | 1.89% | 2018-07-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 55922 | 0.06% | -- | -- | 2018-07-31 |
| Schwab Small Cap Index | 93000 | 0.11% | -- | -- | 2018-07-31 |
| BlackRock Extended Equity Market K | 93463 | 0.11% | 2541 | 2.79% | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 874637 | 1.01% | -- | -- | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 604372 | 0.70% | 2624 | 0.44% | 2018-07-31 |
| iShares Russell 2000 Growth | 441117 | 0.46% | -425 | -0.10% | 2018-09-12 |
| Royce Smaller-Companies Growth Svc | 120000 | 0.14% | 120000 | -- | 2018-06-30 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 121020 | 0.14% | 76 | 0.06% | 2018-07-31 |
| iShares Micro-Cap | 133898 | 0.14% | -- | -- | 2018-09-12 |
| LVIP SSgA Small Cap Index Std | 44500 | 0.05% | 44500 | -- | 2018-06-30 |
| iShares Russell 2000 Value | 49946 | 0.06% | -- | -- | 2018-08-01 |
| Master Small Cap Index | 35272 | 0.04% | 35272 | -- | 2018-06-30 |
| BNY Mellon EB DL Small Cap SIF | 34645 | 0.04% | 34645 | -- | 2018-06-30 |
| Vanguard Russell 2000 Growth ETF | 32411 | 0.04% | 32411 | -- | 2018-06-30 |
| Vanguard Balanced Index Inv | 31240 | 0.04% | 10800 | 52.84% | 2018-06-30 |
| BlackRock Russell 3000 | 15101 | 0.02% | 15101 | -- | 2018-06-30 |
| iShares Russell 3000 | 16756 | 0.02% | -- | -- | 2018-07-12 |
| Pacific Select Small-Cap Index I | 18950 | 0.02% | 18950 | -- | 2018-06-30 |
| Northern Small Cap Index | 29323 | 0.03% | 29323 | -- | 2018-06-30 |
| iShares Core S&P Total US Stock Mkt | 13795 | 0.02% | 6 | 0.04% | 2018-07-05 |
| BNY Mellon EB DL Mkt Completion | 25269 | 0.03% | 22142 | 708.09% | 2018-03-31 |
| T. Rowe Price Extended Equity Market Idx | 24500 | 0.03% | -- | -- | 2018-03-31 |
| SPDR | 10536 | 0.01% | 266 | 2.59% | 2018-07-03 |
| Wilshire Micro-Cap ETF | 12195 | 0.01% | -- | -- | 2018-07-03 |
| The Vanguard Total Stock Market Index | 9042 | 0.01% | 2400 | 36.13% | 2018-05-31 |
| Schwab Total Stock Market Index | 10961 | 0.01% | 10961 | -- | 2018-05-31 |
| BNY Mellon Market Completion Fund UC1 | 8133 | 0.01% | 6189 | 318.36% | 2018-03-31 |
| AXA/Lord Abbett Micro Cap K | 5972 | 0.01% | -- | -- | 2018-04-30 |
| USAA Extended Market Index | 7740 | 0.01% | -- | -- | 2018-04-30 |
| BlackRock U.S. Equity Market F | 6974 | 0.01% | 739 | 11.85% | 2018-03-31 |
| JHVIT Total Stock Market Index I | 2445 | -- | -- | -- | 2018-04-30 |
| SSgA U.S. Total Market Index Fd Class I | 1033 | -- | -67 | -6.09% | 2017-12-31 |
| Master Extended Market Index Series | 7740 | 0.01% | -- | -- | 2018-01-31 |
| BlackRock LifePath | 19 | -- | 7 | 58.33% | 2016-03-31 |
| BlackRock Extended Equity Market Fund | 15681 | -- | -32 | -0.20% | 2015-09-30 |
| Vanguard US Equity Index | 13382 | -- | -- | -- | 2015-07-31 |
| The Vanguard - Total Stk Mkt Idx Trust. CF | 8174 | -- | -- | -- | 2015-10-31 |
| Mellon Capital EB DL Mkt Completion Fund | 3967 | -- | -- | -- | 2015-09-30 |
| AXA/Lord Abbett Micro Cap Portfolio | 2802 | -- | -- | -- | 2015-09-30 |
| BlackRock U.S. Equity Market Fund | 2651 | -- | -15 | -0.60% | 2015-09-30 |
| Fidelity® NASDAQ Composite Index® Fund | 899 | -- | -- | -- | 2015-09-30 |
| Fidelity Spartan® Total Market Idx Fund | 289 | -- | -- | -- | 2015-09-30 |
| Vanguard Instl Total Stock Market Index | 200 | -- | -22362 | -99.10% | 2015-10-31 |
| Fidelity Spartan® Extended Mkt Indx Fd | 37512 | 0.10% | -- | -- | 2015-09-30 |
| BlackRock LifePath® Index 2060 Fund | 6 | -- | 6 | -- | 2015-06-30 |
| Cynthia Wong Hu | Founder of Women in Bio, Inc., Cynthia Wong Hu currently is COO, Secretary, Vice President & General Counsel at CASI Pharmaceuticals, Inc. In the past Dr. Hu occupied the position of Attorney at Klehr, Harrison, Harvey, Branzburg & Ellers LLP, Attorney at Littman Krooks LLP, Counsel at Voya Insurance & Annuity Co., Senior Attorney at Powell Goldstein LLP and Director at Women in Bio, Inc. She received a graduate degree from Rutgers State University of New Jersey and an undergraduate degree from New York University. |
|---|---|
| Ken Keyong Ren | Ken Keyong Ren is an entrepreneur and businessperson who founded ImmunoVentis, Inc., China Innovation Center for Life Science, Novemed, Inc. and AHT, Inc. and who has been the head of 5 different companies. Dr. Ren is on the board of CASI Pharmaceuticals, Inc. (former Chief Executive Officer & Director). In his past career he held the position of Chief Executive Officer for ImmunoVentis, Inc., Chief Executive Officer at China Innovation Center for Life Science, Chief Executive Officer for Novemed, Inc., Chief Investment Director at CCBI Healthcare Fund, Research Scientist at Pfizer Inc. and President of Accelovance China. He received a doctorate from State University of New York at Buffalo and a doctorate from Shandong Medical University. |
| Franklin Cary Salisbury | Franklin Cary Salisbury is on the board of CASI Pharmaceuticals, Inc. and National Foundation for Cancer Research (former President). Mr. Salisbury received an undergraduate degree from Yale University, a graduate degree from The University of Chicago, a graduate degree from Yale Divinity School and a graduate degree from the University of Georgia School of Law. |
| Rajesh C. Shrotriya | Rajesh C. Shrotriya is on the board of CASI Pharmaceuticals, Inc. and 6 other companies. In the past he was Chairman & Chief Executive Officer at Spectrum Pharmaceuticals, Inc., Executive Director-Worldwide CNS Clinical Research at Bristol-Myers Squibb Co., Chief Scientific Officer & Executive VP at SuperGen, Inc. and Chief Medical Officer & VP-Medical Affairs at MGI PHARMA, Inc. Dr. Shrotriya received an undergraduate degree from Armed Forces Medical College, an undergraduate degree from Dr. Bhim Rao Ambedkar University and a doctorate from The Grant Government Medical College. |
| Wei-Wu He | Founder of OriGene Technologies, Inc., Emerging Technology Partners LLC and Intradigm Corp., Wei-Wu He is an entrepreneur and businessperson who has been at the helm of 6 different companies and presently occupies the position of Chairman of OriGene Technologies, Inc., Chairman at Beijing Genetron Health Gene Technology Co. Ltd., Chairman of Beijing Genetron Biotechnology Co. Ltd., Executive Chairman & Chief Executive Officer of CASI Pharmaceuticals, Inc. and General Partner at Emerging Technology Partners LLC. Wei-Wu He is also on the board of Intradigm Corp., MithraGen, Inc. and Human Longevity, Inc. Dr. He previously was Chairman & Chief Executive Officer of Cytomyx Holdings Plc and President of Human Genome Sciences, Inc. Dr. He received a doctorate from Baylor College of Medicine and an MBA from The Wharton School of the University of Pennsylvania. |
| Zuie Chin Huang | Zuie Chin Huang is a businessperson who has been at the helm of 6 different companies. Currently, he occupies the position of Chairman for XW Laboratories, Inc., Co-Chairman at JHL Biotech, Inc., Chairman for Wuhan Kindstar Co. Ltd., Chairman at Windtree Therapeutics, Inc. and Vice President-Corporate Development for OriGene Technologies, Inc. Mr. Huang is also Managing Partner at Kleiner Perkins Caufield & Byers China and General Partner for KPCB China Fund II LP and on the board of 7 other companies. He previously occupied the position of President of Anesiva, Inc., Partner at Panacea Venture, Venture Partner at Vivo Capital LLC, Principal at Bristol-Myers Squibb Co., Principal at Tularik, Inc., Principal at GlaxoSmithKline LLC and Project Manager at ALZA Corp. Zuie Chin Huang received an undergraduate degree from the University of California, Berkeley and an MBA from Stanford Graduate School of Business. |
| Cynthia Wong Hu | Founder of Women in Bio, Inc., Cynthia Wong Hu currently is COO, Secretary, Vice President & General Counsel at CASI Pharmaceuticals, Inc. In the past Dr. Hu occupied the position of Attorney at Klehr, Harrison, Harvey, Branzburg & Ellers LLP, Attorney at Littman Krooks LLP, Counsel at Voya Insurance & Annuity Co., Senior Attorney at Powell Goldstein LLP and Director at Women in Bio, Inc. She received a graduate degree from Rutgers State University of New Jersey and an undergraduate degree from New York University. |
| Quan Zhou | Quan Zhou holds the position of General Partner & Managing Director at IDG Capital Partners Co., Ltd. Dr. Zhou is also Managing Member at IDG Technology Venture Investment IV LLC, Managing Member at IDG Technology Venture Investments LP and Managing Member at IDG Technology Venture Investment III LLC and on the board of 8 other companies. In the past he was President at IDG Technology Venture Investment, Inc. Quan Zhou received a graduate degree from Chinese Academy of Sciences, an undergraduate degree from the University of Science & Technology of China and a doctorate from Rutgers State University of New Jersey. |
| Yue Wu | Founder of Crown Bioscience International, Unimicro Technologies, Inc. and Crown Bioscience, Inc., Yue Wu is an entrepreneur is on the board of CASI Pharmaceuticals, Inc., SCILEX Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc. He previously occupied the position of Chief Operating Officer for Unimicro Technologies, Inc., Chief Business Officer for Starvax, Inc., Head-Asian Operations at Burrill & Co. LLC, Chief Business Officer of Starvax International, Inc. (China), President, CEO & Chief Scientific Officer at Crown Bioscience, Inc., President, Chief Executive & Scientific Officer at Crown Bioscience International and Manager-Business Development & Strategic Planning at F. Hoffmann-La Roche Ltd. He received an undergraduate degree from Fudan University, a doctorate and an MBA from the University of California, Berkeley and a graduate degree from the University of Illinois. |
| James E. Goldschmidt | James E. Goldschmidt is President-United States at Sandoz, Inc. and Senior Vice President-Business Development for CASI Pharmaceuticals, Inc. In his past career he occupied the position of Vice President-Business & Commercial Development at TetraLogic Pharmaceuticals Corp., Vice President-Business Development of ImmuneXcite, Inc., Product Director at GlaxoSmithKline Plc, Executive Director-Business Development at Johnson & Johnson, Chief Operating Officer for Macrophage Therapeutics, Inc. and Executive Director-Oncology New Business at Wyeth Pharmaceuticals LLC. Dr. Goldschmidt received an undergraduate degree from Villanova University, a graduate degree from Drexel University and a doctorate from Temple University School of Medicine. |
| Alexander A. Zukiwski | Alexander A. Zukiwski holds the position of Chief Medical Officer of CASI Pharmaceuticals, Inc. In his past career he was President, CEO, Director & Chief Medical Officer at Arno Therapeutics, Inc., Principal at Johnson & Johnson and Chief Medical Officer & SVP-Clinical Research at MedImmune LLC. He received an undergraduate degree from the University of Alberta and a doctorate from the University of Calgary. |
| George Chi | Presently, George Chi occupies the position of Chief Financial & Accounting Officer at CASI Pharmaceuticals, Inc. In his past career he occupied the position of Chief Financial Officer for Bpl Plasma, Inc. and Vice President-Finance for Flavors Holdings, Inc. He received an undergraduate degree from Tsinghua University and an MBA from Yale School of Management. |
| Wei Zhang | Wei Zhang is President-CASI China at CASI Pharmaceuticals, Inc. In the past Mr. Zhang was Chief Executive Officer of Sandoz China Pharmaceutical Co. Ltd. and President for Casi Beijing Pharmaceuticals Co. Ltd. Mr. Zhang received an undergraduate degree and a graduate degree from the University of Science & Technology of China and an MBA from the University of California, Los Angeles. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论